BGA
GYRE icon

Belmont Global Advisors’s Gyre Therapeutics GYRE Stock Holding History

Belmont Global Advisors’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-197
Closed -$643K – 123
2013
Q4 		$643K Buy
+197
New +$777K 0.52% 52

Other funds holding GYRE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Belmont Global Advisors's GYRE Position: Q1 2014 in Review

Belmont Global Advisors sold out of Gyre Therapeutics (GYRE) in Q1 2014, closing a stake of 197 shares — an estimated $643K sold.

Belmont Global Advisors first reported a position in GYRE in Q4 2013 and held it in 1 quarter. The position peaked at $643K in Q4 2013. 64 funds tracked by Wall St. Rank hold GYRE as of Q1 2014.

  • Belmont Global Advisors reported no remaining Gyre Therapeutics position as of Q1 2014 after selling out during the quarter.
  • Belmont Global Advisors sold 197 Gyre Therapeutics shares in Q1 2014, an estimated $643K.
  • Belmont Global Advisors first reported a position in Gyre Therapeutics in Q4 2013 and held it in 1 quarter.
  • Belmont Global Advisors's Gyre Therapeutics position peaked at $643K in Q4 2013.
  • 64 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2014.

Based on Belmont Global Advisors's 13F filing for Q1 2014, filed 13 May 2014.